CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Learn when bonds may outperform stocks for retirement, with practical timing cues and risk considerations.
24,889 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Bitcoin trades near the $63,000 level as a new AI forecast from Microsoft Copilot outlines a 30-day path with a key r...
As UNFI approaches its 2026 earnings call, investors want clarity on margins, growth drivers, and capital strategy. T...
New CPI data renews tensions between Trump’s White House and Fed Chair Warsh, signaling a potential policy clash as i...
Broadcom stock surged on AI optimism, then slipped after earnings. This guide explains how to evaluate a dip, what ri...
With SpaceX poised to hit the public markets, a wave of megadeals led by Elon Musk looms. Analysts warn the IPO could...
President Trump cancels planned Iran strikes, unleashing a rapid response in crypto and energy markets. Bitcoin jumps...
South Florida's investment map is shifting as Griffin expands in Miami and Stephen Ross grows in West Palm Beach, red...
Arm jumps on AI-driven data-center royalties, while Qualcomm climbs on automotive and data-center strength. The chip-...
SpaceX reveals a trillion-dollar revenue forecast, a target far beyond Wall Street estimates and a test of Musk's mos...
Chevron reports record cash flow and a durable dividend, reviving investor debate over its valuation in a volatile en...
Hometap launches a two-tier pricing model for its home equity investments, offering cheaper costs for early settlemen...